360 filings
Page 9 of 18
8-K
wusl10w4hm7c9w
21 May 19
Second generationmicroRNA-29 replacement shows efficacy in blunting fibrosis in the bleomycin model of pulmonary fibrosis when dosed systemically
7:15am
8-K
yldifkb
8 May 19
Miragen Announces First Quarter 2019 Financial Results
4:01pm
DEFA14A
lxhkx1anpi3ik3w3yasu
3 May 19
Additional proxy soliciting materials
4:46pm
8-K
6rpdxe8y6t it
29 Apr 19
Miragen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen
7:16am
8-K
7ofy qlyqf555m0
26 Apr 19
Miragen Announces New Clinical Data for Cobomarsen In Atll Patients at the 19TH
7:15am
S-8
wkdrp0pp
14 Mar 19
Registration of securities for employees
4:16pm
8-K
72zrcavxc
13 Mar 19
Miragen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
4:02pm
8-K
1j5hp
8 Feb 19
Departure of Directors or Certain Officers
4:18pm
8-K
9lokhz
24 Jan 19
Entry into a Material Definitive Agreement
4:08pm
8-K
xirhfnk
10 Jan 19
Miragen Announces New Clinical Data In Patients with Three Different Types of Blood Cancers Treated with Cobomarsen
7:21am
8-K
muy087h3
20 Dec 18
Other Events
7:15am
8-K
klnbaskz dybg10p1s5z
6 Dec 18
Miragen Therapeutics Announces Board of Director Evolution and Appointment of
7:15am
8-K
fp67jg nb
3 Dec 18
Other Events
7:16am
CT ORDER
nxr1j 7eizbx
19 Nov 18
Confidential treatment order
1:25pm
8-K
dxgmy
7 Nov 18
Miragen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
4:02pm
8-K
acqi8h07m2egh
1 Oct 18
Regulation FD Disclosure
12:00am